Results 1 to 10 of about 117,808 (299)

Amyloid-Beta Peptides Trigger Aggregation of Alpha-Synuclein In Vitro [PDF]

Molecules, 2020
Alzheimer’s disease (AD) and Parkinson’s disease (PD), including dementia with Lewy bodies (DLB), account for the majority of dementia cases worldwide.
Janett Köppen, Anja Schulze, Lisa Machner, Michael Wermann, Rico Eichentopf, Max Guthardt, Angelika Hähnel, Jessica Klehm, Marie-Christin Kriegeskorte, Maike Hartlage-Rübsamen, Markus Morawski, Stephan von Hörsten, Hans-Ulrich Demuth, Steffen Roßner, Stephan Schilling   +14 more
doaj   +4 more sources

Early Divergence in Misfolding Pathways of Amyloid-Beta Peptides. [PDF]

Chemphyschem, 2021
AbstractThe amyloid cascade hypothesis proposes that amyloid‐beta (Aβ) aggregation is the initial triggering event in Alzheimer's disease. Here, we utilize NMR spectroscopy and monitor the structural dynamics of two variants of Aβ, Aβ40 and Aβ42, as a function of temperature.
Mamone S, Glöggler S, Becker S, Rezaei-Ghaleh N.   +3 more
europepmc   +6 more sources

DHA supplemented in peptamen diet offers no advantage in pathways to amyloidosis: is it time to evaluate composite lipid diet? [PDF]

PLoS ONE, 2011
Numerous reports have documented the beneficial effects of dietary docosahexaenoic acid (DHA) on beta-amyloid production and Alzheimer's disease (AD).
Zareen Amtul, Mary Keet, Lin Wang, Peter Merrifield, David Westaway, Richard F Rozmahel   +5 more
doaj   +1 more source

Characterizing Heparin Tetrasaccharides Binding to Amyloid-Beta Peptide [PDF]

Frontiers in Molecular Biosciences, 2022
The aggregation of β-amyloid peptide (Aβ) is one potential cause for Alzheimer’s disease (AD). Heparin can either promote or inhibit Aβ aggregation. The sulfation pattern and chain size determine its binding affinity and its role. Using 2D-NMR analysis and molecular modelling, the binding motif of heparin oligoaccharides to Aβ was determined to be HexA-
Xiang Zhou, Yuanyuan Wang, Wei Zheng, Guangxiu Deng, Fuyi Wang, Lan Jin   +5 more
openaire   +3 more sources

Western Agarose Native GeELution (WANGEL) with beta-amyloid and tau: Novel method to elute proteins or peptides using native agarose gels followed by Lumipulse assay

MethodsX, 2022
Alzheimer´s disease is characterized by hyperphosphorylated tau neurofibrillary tangles and beta-amyloid plaques. Both molecules can be easily measured in human fluids or tissue extracts by immunoassays.
Dhwani S. Korde, Christian Humpel
doaj   +1 more source

Engineering neprilysin activity and specificity to create a novel therapeutic for Alzheimer's disease. [PDF]

PLoS ONE, 2014
Neprilysin is a transmembrane zinc metallopeptidase that degrades a wide range of peptide substrates. It has received attention as a potential therapy for Alzheimer's disease due to its ability to degrade the peptide amyloid beta.
Carl I Webster, Matthew Burrell, Lise-Lotte Olsson, Susan B Fowler, Sarah Digby, Alan Sandercock, Arjan Snijder, Jan Tebbe, Ulrich Haupts, Joanna Grudzinska, Lutz Jermutus, Christin Andersson   +11 more
doaj   +1 more source

The orphan drug dichloroacetate reduces amyloid beta-peptide production whilst promoting non-amyloidogenic proteolysis of the amyloid precursor protein.

PLoS ONE, 2022
The amyloid cascade hypothesis proposes that excessive accumulation of amyloid beta-peptides is the initiating event in Alzheimer's disease. These neurotoxic peptides are generated from the amyloid precursor protein via sequential cleavage by β- and γ ...
Edward T Parkin, Jessica E Hammond, Lauren Owens, Matthew D Hodges   +3 more
doaj   +1 more source

Recent advancements in nanomaterials-based electrochemiluminescent and photoelectrochemical techniques for the determination of beta-amyloid peptides

International Journal of Electrochemical Science, 2022
Beta-amyloid (Aβ) peptides have been considered as the core biomarkers for early diagnosis of Alzheimer's disease. Electrochemiluminescent (ECL) and photoelectrochemical (PEC) biosensors are two promising methods for disease diagnosis in view of their ...
Yunxiao Feng, Ming La
doaj   +1 more source

A γ-secretase inhibitor, but not a γ-secretase modulator, induced defects in BDNF axonal trafficking and signaling: evidence for a role for APP. [PDF]

, 2015
Clues to Alzheimer disease (AD) pathogenesis come from a variety of different sources including studies of clinical and neuropathological features, biomarkers, genomics and animal and cellular models. An important role for amyloid precursor protein (APP)
Cheng, Soan, Goldstein, Lawrence SB, Mobley, William C, Natera-Naranjo, Orlangie, Nguyen, Phuong, Pearn, Matthew L, Reyna, Sol M, Tanzi, Rudolph E, Wagner, Steven L, Weissmiller, April M, Wu, Chengbiao, Zhao, Xiaobei   +11 more
core   +5 more sources

Early Treatment Critical: Bexarotene Reduces Amyloid-Beta Burden In Silico. [PDF]

PLoS ONE, 2016
Amyloid-beta peptides have long been implicated in the pathology of Alzheimer's disease. Bexarotene, a drug approved by the U.S. Food and Drug Administration for treating a class of non-Hodgkin's lymphoma, has been reported to facilitate the removal of ...
Joseph Rosenthal, Georges Belfort, David Isaacson   +2 more
doaj   +1 more source